U.S. Markets closed

Trius announces positive results from ESTABLISH 2 Phase 3 trial of TR-701

Trius Therapeutics announced top-line results from its ESTABLISH 2 Phase 3 clinical trial of tedizolid phosphate, or TR-701, for the treatment of acute bacterial skin and skin structure infections, or ABSSSI, including methicillin resistant Staphylococcus aureus, or MRSA. As in the ESTABLISH 1 study, which tested the oral dosage form of tedizolid, the ESTABLISH 2 intravenous to oral transition study captured the endpoints for ABSSSI established by both the FDA and the European Medicines Agency.